Popular terms

[SEARCH]

Autoimmune topics
Autoimmune
Immune Disease
Autoimmune Disease
Immune Diseases
Autoimmune Diseases
Transplant
Immune Disorder
Autoimmune Disorder
Autoimmune Disorders
Infectious
Infectious Disease
Inflammatory Disease
Type 1 Diabetes
Proliferative Disorder
Recurrence

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Autoimmune patents



      
           
This page is updated frequently with new Autoimmune-related patent applications. Subscribe to the Autoimmune RSS feed to automatically get the update: related Autoimmune RSS feeds. RSS updates for this page: Autoimmune RSS RSS



Date/App# patent app List of recent Autoimmune-related patents
07/30/15
20150210982 
 Isolation and use of human regulatory t cells patent thumbnailnew patent Isolation and use of human regulatory t cells
The present invention provides a new method for isolating and enriching human regulatory t cells. The enriched cells are useful in the treatment of autoimmune disease..
Biogen Idec Ma Inc.


07/30/15
20150210703 
 Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases patent thumbnailnew patent Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof. The formula i compounds inhibit tyrosine kinase activity of jak3, thereby making them useful for the treatment of inflammatory and autoimmune diseases..
Bristol-myers Squibb Company


07/30/15
20150209410 
 Compositions and methods relating to the treatment of diseases patent thumbnailnew patent Compositions and methods relating to the treatment of diseases
A method is provided for the treatment and/or prophylaxis of a condition where an enhancement of a th1-mediated immune response and suppression of a th2/th17-mediated immune response are desired. The method comprises the step of administering to a subject in need thereof a therapeutically effective amount of at least one interferon alpha subtype selected from ifn-α10, ifn-α14, and a hybrid thereof.
Alfacyte, Ltd.


07/30/15
20150209348 
 Histamine 4 receptor partial agonists, inverse agonists or antagonists for use in treating non-autoimmune uveitis patent thumbnailnew patent Histamine 4 receptor partial agonists, inverse agonists or antagonists for use in treating non-autoimmune uveitis
The invention provides a compound which is a histamine 4 receptor antagonist, partial agonist or inverse agonist, for use in the treatment of non-autoimmune uveitis. The compound preferably has a structural core comprising a substituted pyrimidine group, such as an aminopyrimidine, diaminopyrimidine or triaminopyrimidine group, a thienopyrimidine, a furopyrimidine, a benzimidazole, an aryl or heteroaryl-fused pyrimidine, an indole, a bicyclic heteroaryl-substituted imidazole or a quinazoline group..
Ucl Business Plc


07/23/15
20150204871 
 Automated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases patent thumbnailAutomated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases
A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.. .
Hycor Biomedical, Inc.


07/23/15
20150204867 
 Automated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases patent thumbnailAutomated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases
A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.. .
Hycor Biomedical, Inc.


07/23/15
20150203851 
 Inhibitors of bromodomain-containing protein pcaf for the treatment of autoimmune and inflammatory diseases or for the treatment of cancer patent thumbnailInhibitors of bromodomain-containing protein pcaf for the treatment of autoimmune and inflammatory diseases or for the treatment of cancer
A method of treating autoimmune and inflammatory diseases or conditions or cancer in a mammal, such as a human, which comprises the administration of an inhibitor of the bromodomain-containing protein pcaf.. .
Glaxo Group Limited


07/23/15
20150203847 
 Chemical modifications of monomers and oligonucleotides with cycloaddition patent thumbnailChemical modifications of monomers and oligonucleotides with cycloaddition
In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression..

07/23/15
20150203820 
 Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof patent thumbnailMesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
The present invention relates to methods of generating and expanding hitman embryonic stem eel! derived mesenchymal-like stem/siromal cells. These hes-mscs are characterized at least in part by the low level of expression of il-6.
Imstem Biotechnology, Inc.


07/23/15
20150203579 
 Human antibodies to pd-1 patent thumbnailHuman antibodies to pd-1
The present invention provides antibodies that bind to the t-cell co-inhibitor programmed death-1 (pd-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to pd-1.
Regeneron Pharmaceuticals, Inc.


07/23/15
20150203560 

Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases


The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof for treatment of autoimmune diseases. More specifically, the present invention provides novel genetically engineered fusion molecules comprising an interferon (ifn) molecule attached to an antibody (ab) which targets an antigen which is differentially expressed or up-regulated on activated t cells as compared to resting t cells, wherein the fusion molecule when contacted to an activated t cell results in induced apoptosis and programmed cell death or impairment of functions of said activated t cell..
Immungene Inc.


07/23/15
20150203556 

Compositions and methods for modulation of il-20 family cytokine activity


Provided herein are compositions comprising one or more agents that inhibit or reduce the activity of il-20. Optionally, the agents further inhibit or reduce the activity of il-24.
The Uab Research Foundation


07/23/15
20150203537 

Inhibition of gliadin peptides


Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation


07/23/15
20150203486 

Imidazopyridine derivatives as modulators of tnf activity


A series of imidazo[1,2-a]pyridine derivatives of formula (i), being potent modulators of human tnfa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.. .
Ucb Biopharma Sprl A Corporation


07/23/15
20150203483 

2,3-benzodiazepines


In which r1a, r1b, r1c, r2, r3, r4, r5, a and x have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumour disorders. Also described is the use of bet protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility..

07/23/15
20150203455 

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders


Wherein cy, r1, l1, r3, r4, r5, la, and ra are as defined herein. Novel benzimidazoles according to formula i, able to inhibit jak are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or hypersecretion of interferons..

07/23/15
20150202318 

Aberrant cell-restricted immunoglobulins provided with a toxic moiety


Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an mhc-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes.
Apo-t B.v.


07/23/15
20150202285 

Compositions and methods for modulating immune responses


This invention discloses methods and compositions for modulating immune responses, which involve particulate delivery of agents to immune cells, wherein the agents comprise an inhibitor of the nf-κb signaling pathway and an antigen that corresponds to a target antigen. The methods and compositions of the present invention are particularly useful in the treatment or prophylaxis of an undesirable immune response associated with the target antigen, including autoimmune diseases, allergies and transplantation associated diseases..
The University Of Queensland


07/16/15
20150197551 

Methods and compositions for modulating toso activity


The present invention is further directed to methods and compositions for modulating the activity of the toso protein. The invention further encompasses treatment of disorders associated with inflammation, autoimmune disorders, and cancer using compositions that include a soluble toso protein..
University Health Network


07/16/15
20150197497 

Selective inhibitors of histone deacetylase isoform 6 and methods thereof


The described invention provides histone deacetylase (hdac) inhibitor compounds with substituted benzimidazole, benzimidazolone and benzotriazole heterocycles showing selective inhibition of histone deacetylase isoform hdac6. The described invention further provides methods of making such compounds and methods of inhibiting hdac, treating hdac-associated diseases, including cell proliferative disorders, such as cancer, autoimmune or inflammatory diseases and neurodegenerative diseases..
Dana-farber Cancer Institute, Inc.


07/16/15
20150196517 

Autoimmune disorder treatment using rxr agonists


The present specification provides rxr agonist compounds, compositions comprising such rxr agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such rxr agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.. .
Trustees Of Dartmouth College


07/16/15
20150196511 

Composition comprising metformin as active ingredient for preventing or treating inflammatory bowel disease


The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of il-17 and tnf-a, and promoting or increasing the activity of ifnr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease..
Catholic University Industry Academic Cooperation Foundation


07/09/15
20150192582 

Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs


The invention provides methods of isolating cd127lo/− immunosuppressive regulatory t cells which can be greatly enriched for foxp3, methods of expanding the isolated cells, pharmaceutical compositions of such cells, and methods of their use in the treatment of autoimmune and other immune system mediated disorders.. .
The Regents Of The University Of California


07/09/15
20150191699 

Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof


The disclosure provided herein relates generally to mesenchymal-like stem cells “hes-t-misc” or “t-msc” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hes-t-msc or t-msc, t-msc derived cells and cell lineages “t-msc-dl” are also described.
Imstem Biotechnology, Inc.


07/09/15
20150191546 

Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease


The specification describes the sequences for antibodies that recognize the hla-a2-restricted peptide pr-1 in the context of hla presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided..
Board Of Regents, The University Of Texas System


07/09/15
20150191522 

Compositions for preserving insulin-producing cells and insulin production and treating diabetes


Nuclear transport modifiers such as csn50 and csn50.1, afford in vivo islet protection following a 2-day course of intense treatment in autoimmune diabetes-prone, non-obese diabetic (nod) mice, a widely used model of type 1 diabetes (t1d), which resulted in a diabetes-free state for one year without apparent toxicity and the need to use insulin. Csn50 precipitously reduces the accumulation of islet-destructive autoreactive lymphocytes while enhancing activation-induced cell death of t and b lymphocytes derived from nod mice.
Vanderbilt University


07/09/15
20150191520 

Complement split product c4d for the treatment of inflammatory conditions


The present invention relates to a pharmaceutical composition comprising complement split product c4d for use in treating an inflammatory condition, such as graft rejection, graft versus host disease, an autoimmune disease or atopy. The c4d to be used may be a multimer.
Medizinische Universität Wien


07/09/15
20150191503 

Organic compounds


This invention relates to sphingoglycolipid analogues, compositions comprising these compounds, processes for preparing the compounds, and methods of treating or preventing diseases or conditions using the compounds, such as diseases or conditions relating to infection, atopic disorders, autoimmune disease, diabetes or cancer.. .
Callaghan Innovation Research Limited


07/09/15
20150191483 

Pyrrolidinyl sulfone rorgamma modulators


Or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same.

07/09/15
20150191482 

Imidazopyrazine derivatives as modulators of tnf activity


A series of imidazo[1,2-α]pyrazine derivatives, being potent modulators of human tnfα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorder; and oncological disorders.. .
Ucb Biopharma Sprl


07/09/15
20150191466 

Tropomyosin-related kinase (trk) inhibitors


Tropomyosin-related kinase inhibitors (trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions.
Genzyme Corporation


07/09/15
20150191464 

Heteroaryl substituted nicotinamide compounds


Or salts thereof, wherein: het is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1h-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with ra and rb; and r1 and r2 are define herein. Also disclosed are methods of using such compounds as modulators of irak4, and pharmaceutical compositions comprising such compounds.

07/09/15
20150191417 

Anti-proliferative compounds and uses thereof


The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, tautomers, stereoisomers, solvates, hydrates, polymorphs, and compositions thereof. Also provided are methods and kits involving the inventive compounds for treating proliferative diseases (e.g., cancers (e.g., breast cancer, prostate cancer, lung cancer, and ovarian cancer), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases) in a subject.
The General Hospital Corporation D/b/a Massachusetts General Hospital


07/02/15
20150184165 

Immunosuppression compound and treatment method


A method and compound for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection are disclosed. The compound is an antisense oligonucleotide analog compound having a targeting sequence complementary to a preprocessed ctla-4 mrna region identified by seq id no: 22 in seq id no: 1, spanning the splice junction between intron 1 and exon 2 of the preprocessed mrna of the subject.
Sarepta Therapeutics, Inc.


07/02/15
20150183856 

Novel monoclonal antibody binding specifically to dll4 and use thereof


The present invention relates to a novel monoclonal antibody that binds specifically to delta-like ligand (dll4), and more particularly to a monoclonal antibody that binds specifically to human delta-like ligand 4 to effectively inhibit the interaction between delta-like ligand 4 and notch receptor, a polynucleotide encoding the monoclonal antibody, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the monoclonal antibody, a pharmaceutical composition for preventing or treating cancer comprising the monoclonal antibody, a composition for diagnosing cancer comprising the monoclonal antibody, a method for diagnosing cancer using the monoclonal antibody, and a pharmaceutical composition for preventing or treating autoimmune disease comprising the monoclonal antibody.. .
Hanwha Chemical Corporattion


07/02/15
20150183834 

Filoviral immunosuppressive peptides


The invention provides a region of strong secondary structure conservation between the c-terminus domain of the envelope glycoprotein of filoviruses and an immunosuppressive domain found in retroviral envelope glycoproteins. The invention provides filoviral peptides and modified derivatives thereof with strong immunosuppressive bioactivity.
The Trustees Of Columbia University In The City Of New York


07/02/15
20150183805 

Processes and intermediates for making a jak inhibitor


This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of janus kinases (jak) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.. .
Incyte Corporation


07/02/15
20150183775 

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
Abbvie Inc.


07/02/15
20150182592 

Composition comprising at least two compounds which induce indolamine 2,3 - dioxygenase (ido), for the treatment of an autoimmune disorder or suffering from immune rejection of organs


A composition and method for using a composition, the composition having at least two compounds, each of which induces indolamine 2,3-dioxygenase, for the treatment of an autoimmune disorder or disease or immune rejection of transplants or gene therapeutically modified cells, wherein the inducers have different mechanism of action and wherein the composition gives rise to a synergistic effect on the ido levels.. .
Idogen Ab


07/02/15
20150182566 

Lactic acid bacterium-containing preparation


An object of the present invention is to provide a useful composition that contains a highly safe lactic acid bacterium or a component derived from this lactic acid bacterium. The present invention relates to a composition comprising at least one lactic acid bacterium selected from the group consisting of lactobacillus delbrueckii subsp.
Kaneka Corporation


07/02/15
20150182539 

Pregnancy hormone combination for treatment of autoimmune diseases


The present invention relates to pregnancy hormone combinations and methods of treatment for autoimmune diseases having at least two hormonal components, a pregnancy hormone (such as estriol), and a gestagen (such as levonorgestrel or norethindrone) thereby providing for the continuous, uninterrupted administration of pregnancy hormones for the treatment for autoimmune disorders, such as multiple sclerosis.. .
The Regents Of The University Of California




Popular terms: [SEARCH]

Autoimmune topics: Autoimmune, Immune Disease, Autoimmune Disease, Immune Diseases, Autoimmune Diseases, Transplant, Immune Disorder, Autoimmune Disorder, Autoimmune Disorders, Infectious, Infectious Disease, Inflammatory Disease, Type 1 Diabetes, Proliferative Disorder, Recurrence

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Autoimmune for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.4472

5715

459570 - 0 - 112